BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2016

Nov 23, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2016-11-21

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-11-21	Common Stock	M	69744	$26.490	Acquired	240426	Direct
2016-11-21	Common Stock	S	69744	$87.5556	Disposed	170682	Direct
2016-11-22	Common Stock	M	69743	$26.490	Acquired	240425	Direct
2016-11-22	Common Stock	S	69743	$85.6934	Disposed	170682	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-11-21	Stock Option (right to buy Common Stock)	$26.49	M	69744	Disposed	2021-05-11	Common Stock (69744)	Direct
2016-11-22	Stock Option (right to buy Common Stock)	$26.49	M	69743	Disposed	2021-05-11	Common Stock (69743)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	182801	Indirect

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime.

F2: The amount of securities beneficially owned has been updated from the reporting person's prior Form 4 to reflect (a) changes in the form of ownership due to transfers made by the reporting person between accounts held directly and indirectly in the name of the Bienaime Family Trust and the Jean-Jacques Bienaime Family Trust and (b) an additional 4,357 shares beneficially owned by the reporting person pursuant to a reconciliation of the Company's records following the completion of the transfer of shares in connection with the reporting person's marital separation agreement.

F3: The price in column 4 is the weighted average price. The price actually received ranged from $86.74 to $89.59. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F4: The price in column 4 is the weighted average price. The price actually received ranged from $84.45 to $88.16. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F5: Reflects the number of stock options outstanding after the transaction from this specific stock option grant.